


Therapiealgorithmus der Deutschen Atemwegsliga

für das nicht-kleinzellige Lungenkarzinom (NSCLC)
Stadium IV



Deutsche Atemwegsliga e.V.

NSCLC ohne Treibermutation



	Freiname	Handelsname
Immunonkologika	Atezolizumab	Tecentric
	Nivolumab	Opdivo
	Pembrolizumab	Keytruda
VEGFR-AK	Ramucirumab	Cyramza
VEGFR-TKI	Nintedanib	Vargatef
EGFR-AK	Necitumumab	Portrazza

Abkürzungen:

EGFR (Epidermal Growth Factor Receptor)
VEGF (Vascular Endothelial Growth Factor)

ALK (Anaplastische Lymphom-Kinase)
ROS (Reactive Oxygen Species)

PD-L1 (Programmed Death-Ligand 1)
TKI (Tyrosinkinaseinhibitor)